Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Mark M. Awad, Xinan Wang et al.|JAMA Oncology|2022Cited by 383
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung CancerBiagio Ricciuti, Mark M. Awad, Giuseppe Lamberti et al.|Journal of Clinical Oncology|2024Cited by 124
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancerShunsuke Kitajima, David A. Barbie, Tetsuo Tani et al.|Cancer Cell|2022Cited by 101
<i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor ImmunityTetsuo Tani, David A. Barbie, Haritha Mathsyaraja et al.|Cancer Discovery|2024Cited by 98
Activation of Tumor-Cell STING Primes NK-Cell TherapyErik H. Knelson, David A. Barbie, Elena V. Ivanova et al.|Cancer Immunology Research|2022Cited by 88